Compass Therapeutics’s stock crashes after OS miss in BTC trial
Compass Therapeutics’ stock has dropped by more than 60% after a Phase II/III trial of its biliary tract cancer (BTC)…
Oncology
-
-
Storm clinches $56m in Series C for Phase II on lead sarcoma drug
British cancer biotech Storm Therapeutics has secured $56m in a Series C financing round to push its sarcoma therapy, STC-15,…
-
PDS Biotech’s stock up on colorectal cancer trial success
PDS Biotech’s stock has jumped nearly 25% after its tumour-targeting fused antibody drug conjugate (ADC) elicited a 78% response in patients…
-
Lilly’s Jaypirca racks up fourth Phase III CLL win
Eli Lilly’s Jaypirca (pirtobrutinib) has succeeded in its fourth Phase III trial in chronic lymphocytic leukaemia (CLL). The Phase III…
-
Never-married individuals reported to have higher cancer risk
Cancer is the leading cause of death globally, accounting for one in six deaths worldwide in 2020, according to the…
-
AbbVie’s Elahere succeeds in Phase II platinum-sensitive ovarian cancer trial
AbbVie’s Elahere has shown a 62.7% objective response rate (ORR) in patients with platinum-sensitive ovarian cancer (PSOC) in a Phase…
-
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
BioNTech and DualityBio reported encouraging data from a Phase II cohort of their global clinical study evaluating the efficacy of…
-
Verastem Oncology’s combo shows two-year durability in ovarian cancer
Verastem Oncology’s combination therapy has shown durability in patients with recurrent low-grade serous ovarian cancer (LGSOC). The data, presented during…
-
Oric to advance prostate cancer drug to Phase III trials
ORIC Pharmaceuticals will advance its prostate cancer drug to Phase III trials after it showed survival benefit in a Phase…
-
Karyopharm’s Phase III myelofibrosis trial delivers mixed results
Karyopharm Therapeutics’ latest Phase III trial for its rare blood cancer drug produced a hit and a miss, achieving one…
